Obesity Linked With Prostate Cancer Death
A body mass index of 30 kg/m2 or higher was was associated with 2-fold increased risk of dying from prostate cancer.
A body mass index of 30 kg/m2 or higher was was associated with 2-fold increased risk of dying from prostate cancer.
Based on a small study, investigators report encouraging efficacy and safety.
Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting.
In a study, a drop in alkaline phosphatase level at 12 weeks compared with baseline was associated with a decreased risk of death and first symptomatic skeletal event.
Use of the drug is associated with significantly longer progression-free survival compared with suninitib in treatment-naïve patients.
Current smoking was linked with higher risks for lung cancer and upper aerodigestive cancer by 9 and 5 times, respectively.
Bone turnover markers increased following unilateral nephrectomy.
Within each D’Amico risk category, African-American and Hispanic prostate cancer patients were less likely to receive definitive treatment than white patients.